Engage Therapeutics, Inc.

Engage Therapeutics, Inc. is a biopharmaceutical company focused on innovative therapies for patients with epilepsy, aiming to improve treatment outcomes through advanced scientific research and personalized support services. Engage Therapeutics, Inc. is dedicated to developing treatments for epilepsy, formed in 2017 and headquartered in Summit, US.

In June 2020, Engage was acquired by Three Manufacturing Sites From UCB for USD 125 mn, following three funding deals. The founder has a history in the biopharmaceutical sector but specific details about prior ventures are not available. UCB S. A.

specializes in the development and commercialization of innovative therapies for neurological and autoimmune conditions. Their key products include the biologic medication Cimzia® for autoimmune conditions and Vimpat® for epilepsy management. UCB also offers personalized support through UCBCares®, assisting patients and healthcare providers with treatment options, with products available across North America, Europe, and select Asian markets. UCB S.

A. generates revenue via direct sales of its medications to healthcare providers, hospitals, and specialty pharmacies, focusing on B2B transactions. The pricing strategy typically involves negotiated contracts, influenced by reimbursement policies and market access strategies, ensuring vital treatments are accessible to both providers and patients. UCB also partners with other pharmaceutical companies to enhance its revenue streams.

Engage Therapeutics plans to leverage recent funding from the acquisition by UCB to further develop their epilepsy treatment solutions. The capital from the USD 125 mn deal, including upcoming milestone payments, will support the launch of new products and expansion into additional global markets, enhancing their reach and therapeutic offerings.